Mayo Clinic | Strategic Alliance Partners

March 01, 2021

Yttrium-90 glass microspheres administered in a personalized, dosimetric approach demonstrated a 16-month improvement in overall survival compared with a standard dosimetric approach in patients with unresectable hepatocellular carcinoma.

February 27, 2021

Targeted therapies have helped to improve responses in patients with relapsed chronic lymphocytic leukemia regardless of high-risk disease, although optimal sequencing and toxicity management need to be further explored to strengthen the utilization of these options.

February 26, 2021

Tanios S. Bekaii-Saab, MD, FACP, shares his approach for treating patients with HCC across several lines of therapy, as well as factors to consider when making sequencing decisions.

February 23, 2021

Joleen M. Hubbard, MD, discusses identifying disease progression in patients with colorectal cancer.

February 18, 2021

Kabir Mody, MD discusses new directions with yttrium-90 glass microspheres in hepatocellular carcinoma as demonstrated in the retrospective LEGACY study.

February 18, 2021

Yi Lin, MD, PhD, discusses promising data with CAR T-cell therapy in multiple myeloma.

February 18, 2021

Rafael Fonseca, MD, discusses several clinical trials that support the use of quadruplet regimens in myeloma, the utilization of MRD in clinical decision-making, and future directions for research.

February 10, 2021

Sikander Ailawadhi, MD, discusses the future of relapsed/refractory multiple myeloma, the potential for retreatment with proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies, and the promise of T-cell engagers in the field.

February 08, 2021

Yttrium-90 glass microspheres, a personalized radiotherapeutic cancer treatment, induced an overall response rate of 72.2% per blinded independent central review as neoadjuvant or stand-alone treatment in 143 evaluable patients with unresectable hepatocellular carcinoma.

January 28, 2021

Kabir Mody, MD, discusses the unique approach used to deliver Y-90 glass microspheres to patients with unresectable hepatocellular carcinoma.

January 27, 2021

Shaji K. Kumar, MD, discusses treatment selection considerations in multiple myeloma.

January 27, 2021

January 27, 2021 - The combination of the polo-like kinase 1 inhibitor, onvansertib, with FOLFIRI and bevacizumab was found to have preliminary activity and favorable tolerability when used as a second-line treatment for patients with KRAS-mutated metastatic colorectal cancer.

January 26, 2021

Rafael Fonseca, MD, discusses the shift toward frontline quadruplet regimens in multiple myeloma.

January 26, 2021

Sikander Ailawadhi, MD, discusses potential combination strategies with selinexor and belantamab mafodotin-blmf in multiple myeloma.

January 22, 2021

Joleen M. Hubbard, MD, discusses sequencing challenges regarding EGFR inhibitors in colorectal cancer.

January 22, 2021

Tanios S. Bekaii-Saab, MD, FACP, discusses indicators of progression in colorectal cancer.

January 21, 2021

Daniel H. Ahn, DO, discusses the growing role of circulating tumor DNA in colorectal cancer.

January 21, 2021

Beau Toskich, MD, discusses key results that demonstrate the benefit of personalized dosimetry, and offered advice to fellow clinicians as the field moves toward adopting this radiotherapeutic modality.

January 20, 2021

Yi Lin, MD, PhD, discusses the importance of developing non-BCMA–targeting agents in multiple myeloma.

January 20, 2021

Shaji K. Kumar, MD, discusses the emergence of minimal residual disease negativity as a surrogate end point in relapsed/refractory multiple myeloma.